Stefano Cascinu

1993–2024 年に発表

165
論文数
19,309
被引用数
79
h 指数
162
i10 指数

被引用数

Stefano Cascinu の年別被引用数1967 年: 被引用 1 件1991 年: 被引用 1 件1994 年: 被引用 1 件1995 年: 被引用 4 件1996 年: 被引用 2 件1997 年: 被引用 6 件1998 年: 被引用 14 件1999 年: 被引用 14 件2000 年: 被引用 18 件2001 年: 被引用 15 件2002 年: 被引用 39 件2003 年: 被引用 36 件2004 年: 被引用 33 件2005 年: 被引用 36 件2006 年: 被引用 54 件2007 年: 被引用 56 件2008 年: 被引用 86 件2009 年: 被引用 133 件2010 年: 被引用 183 件2011 年: 被引用 162 件2012 年: 被引用 173 件2013 年: 被引用 197 件2014 年: 被引用 200 件2015 年: 被引用 166 件2016 年: 被引用 160 件2017 年: 被引用 136 件2018 年: 被引用 118 件2019 年: 被引用 485 件2020 年: 被引用 575 件2021 年: 被引用 540 件2022 年: 被引用 396 件2023 年: 被引用 410 件2024 年: 被引用 748 件2025 年: 被引用 301 件2026 年: 被引用 6 件1968〜1990 年は被引用が無いため表示していません1992〜1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,418 件、この内訳の 17%中国: 引用元論文 1,054 件、この内訳の 12.6%イタリア: 引用元論文 853 件、この内訳の 10.2%イギリス: 引用元論文 641 件、この内訳の 7.7%ドイツ: 引用元論文 432 件、この内訳の 5.2%日本: 引用元論文 349 件、この内訳の 4.2%フランス: 引用元論文 324 件、この内訳の 3.9%スペイン: 引用元論文 300 件、この内訳の 3.6%オランダ: 引用元論文 258 件、この内訳の 3.1%オーストラリア: 引用元論文 248 件、この内訳の 3%韓国: 引用元論文 227 件、この内訳の 2.7%カナダ: 引用元論文 216 件、この内訳の 2.6%
0%17%その他 24.2%

分野

  • Medicine77.1%
  • Biochemistry, Genetics and Molecular Biology14.9%
  • Immunology and Microbiology2.5%
  • Health Professions1%
  • Neuroscience0.8%
  • Engineering0.7%
  • その他3%

トピック

  • Colorectal Cancer Treatments and Studies6.9%
  • Gastric Cancer Management and Outcomes4.3%
  • Cancer Immunotherapy and Biomarkers3.9%
  • Pancreatic and Hepatic Oncology Research3.2%
  • Hepatocellular Carcinoma Treatment and Prognosis3%
  • Cancer Genomics and Diagnostics2.6%
  • その他76.1%

共著者

全論文

検索で開く
  1. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , - Annals of Oncology 2022 被引用: 1,382

  2. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 1,887

  3. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Florian Kühn, Luigi Laghi, Andrew Latchford, David Liska, Patrick M. Lynch, Alberto Malesci, Gianluca Mauri, Elisa Meldolesi, Pål Møller, Kevin Monahan, Gabriela Möslein, Caitlin C. Murphy, Karlijn J. Nass, Kimmie Ng, Cristina Oliani, Enrico Papaleo, Swati Patel, Marta Puzzono, Andrea Remo, Luigi Ricciardiello, Carla Ripamonti, Salvatore Siena, Satish K. Singh, Zsofia K. Stadler, Peter P. Stanich, Sapna Syngal, Stefano Turi, Emanuele Damiano Luca Urso, Laura Valle, Valeria Stella Vanni, Eduardo Vilar, Marco Vitellaro, Yiqian Nancy You, Matthew B. Yurgelun, Raffaella Alessia Zuppardo, Elena M. Stoffel - Clinical Gastroenterology and Hepatology 2022 被引用: 125

  4. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mara Persano, Eleonora Gusmaroli, Riccardo Cerantola, Francesca Salani, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu, Lorenza Rimassa, Lorenzo Antonuzzo, Andrea Casadei‐Gardini - Liver International 2023 被引用: 117

  5. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takuya Sho, Beodeul Kang, Antonio D’Alessio, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiro Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, T. Nishimur, Takeshi Hatanaka, Satoru Kakizaki, Naohiko Shimada, Kazuhito Kawata, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, T. Arai, Michitaka Imai, Atsushi Naganuma, Yuichiro Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Federica Pedica, Francesco De Cobelli, Francesca Ratti, Luca Aldrighetti, Masatoshi Kudo, Stefano Cascinu, Andrea Casadei‐Gardini - ESMO Open 2022 被引用: 130

  6. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

    著者: , , , , , , , , - Pancreatology 2014 被引用: 507

  7. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti - European Journal of Cancer 2022 被引用: 129

  8. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

    著者: , , , , , , , , , , , - The Lancet Oncology 2014 被引用: 470

  9. The evolving role of microsatellite instability in colorectal cancer: A review

    著者: , , , , - Cancer Treatment Reviews 2016 被引用: 333

  10. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giovanni Di Costanzo, Fabio Marra, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Claudia Campani, Elisabeth Amadeo, Federico Rossari, Valentina Burgio, Stefano Cascinu, Mario Scartozzi, Andrea Casadei‐Gardini - European Journal of Cancer 2023 被引用: 56

  11. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2012 被引用: 213

  12. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials

    著者: , , , , , , , , , , , - International Journal of Surgery 2018 被引用: 181

  13. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Oncologist 2018 被引用: 143

  14. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights

    著者: , , , , , , , , - International Journal of Molecular Sciences 2019 被引用: 161

  15. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark I. van Berge Henegouwen, Maarten C.C.M. Hulshof, Jolanda van Dieren, Marieke A. Vollebergh, Johanna W. van Sandick, Paul M. Jeene, C.T. Muijs, Marije Slingerland, Francine E.M. Voncken, Henk H. Hartgrink, Geert-Jan Creemers, Maurice J.C. van der Sangen, Grard A. P. Nieuwenhuijzen, Maaike Berbée, Marcel Verheij, Bas P. L. Wijnhoven, Laurens V. Beerepoot, Nadia Haj Mohammad, Stella Mook, Jelle P. Ruurda, Piotr Kołodziejczyk, Wojciech Polkowski, Lucjan Wyrwicz, María Alsina, Manuel Pera, Tania Fleitas, Andrés Cervantes, Magnus Nilsson, Stefan Mönig, Dorothea Wagner, Matthias Gückenberger, Ewen A. Griffiths, Elizabeth Smyth, George B. Hanna, Sheraz R. Markar, M. Asif Chaudry, M. Hawkins, Edward Cheong, Richard van Hillegersberg, Peter S.N. van Rossum, Tom Rozema, Joos Heisterkamp, Markus Schaefer, E.M. Ozsahin, Jacco J. de Haan, Jan Willem van den Berg, Frédéric Duprez, Eduard Callebout, Elke Van Daele, Ulrich Hacker, Albrecht Hoffmeister, Thomas Kuhnt, Timm Denecke, Regine Kluge, Gerald W. Prager, Aysegül Ilhan‐Mutlu, Dajana Cuicchi, Andrea Ardizzoni, Camiel Rosman, Elske C. Gootjes, Heidi Rütten, Francesco Puccetti, Stefano Cascinu, N. Slim, Maria Eugenia Barrios, Maria Carmen Fernandez, Roberto Martí-Oriol, Marisol Huerta Alvaro, Almudena Vera, E. Jordá ほか 10 名 - European Journal of Cancer 2023 被引用: 53

  16. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Oncologist 2020 被引用: 112

  17. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?

    著者: , , , , , , , , , , , - European Journal of Surgical Oncology 2016 被引用: 140

  18. Class 1, 2, and 3 BRAF -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 107

  19. Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2018 被引用: 85

  20. A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Federica Morano, Elena Ongaro, Stefano Cascinu, Daniele Santini, Pina Ziranu, Marta Schirripa, Federica Buggin, Alessandra Anna Prete, Ilaria Depetris, Paola Biason, Sara Lonardi, Vittorina Zagonel, Matteo Fassan, Massimo Di Maïo - European Journal of Cancer 2019 被引用: 70

  21. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

    著者: , , , , , , , , , , , , , - Cancer Immunology Immunotherapy 2019 被引用: 59

  22. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma

    著者: , , , , , , , , , , - Cancer Immunology Immunotherapy 2013 被引用: 148

  23. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies

    著者: , , , , , , , , - Critical Reviews in Oncology/Hematology 2015 被引用: 80

  24. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini - Journal of Cancer Research and Clinical Oncology 2023 被引用: 38